Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women.

Izbicka E, Streeper RT, Michalek JE, Louden CL, Diaz A 3rd, Campos DR.

Cancer Genomics Proteomics. 2012 Jan;9(1):27-35.

PMID:
22210046
2.

A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling.

Lee HJ, Kim YT, Park PJ, Shin YS, Kang KN, Kim Y, Kim CW.

J Thorac Cardiovasc Surg. 2012 Feb;143(2):421-7. doi: 10.1016/j.jtcvs.2011.10.046. Epub 2011 Nov 20.

3.

Detection and significance of serum protein markers of small-cell lung cancer.

Han M, Liu Q, Yu J, Zheng S.

J Clin Lab Anal. 2008;22(2):131-7. doi: 10.1002/jcla.20230.

PMID:
18348318
4.

Application of serum SELDI proteomic patterns in diagnosis of lung cancer.

Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC.

BMC Cancer. 2005 Jul 20;5:83.

5.

Panel of serum biomarkers for the diagnosis of lung cancer.

Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd.

J Clin Oncol. 2007 Dec 10;25(35):5578-83.

PMID:
18065730
6.

Serum microRNA biomarkers for detection of non-small cell lung cancer.

Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, Ochs MF, Ahrendt SA, Mambo E, Califano JA.

PLoS One. 2012;7(2):e32307. doi: 10.1371/journal.pone.0032307. Epub 2012 Feb 28.

7.

Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.

Anticancer Res. 2000 Mar-Apr;20(2B):1311-6.

PMID:
10810441
8.

EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.

Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, Chapman CJ, Allen J, Wood WC, Sewell HF, Robertson JF.

Cancer Prev Res (Phila). 2011 Jul;4(7):1126-34. doi: 10.1158/1940-6207.CAPR-10-0328.

9.

[Application of serum surface-enhanced laser desorption/ionization proteomic patterns in distinguishing non-small cell lung cancer patients from healthy people].

Yang SY, Xiao XY, Zhang WG, Sun XZ, Zhang LJ, Zhang W, Zhou B, Yang DC, He DC.

Zhonghua Jie He He Hu Xi Za Zhi. 2006 Jan;29(1):31-4. Chinese.

PMID:
16638298
10.

Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.

Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E.

Chest. 1995 Jul;108(1):163-9.

PMID:
7541742
11.

[Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].

Mroczko B, Szmitkowski M, Czygier M.

Przegl Lek. 1999;56(12):763-6. Polish.

PMID:
10789186
12.

Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer.

Cai XW, Shedden K, Ao X, Davis M, Fu XL, Lawrence TS, Lubman DM, Kong FM.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):867-76. doi: 10.1016/j.ijrobp.2010.01.038.

PMID:
20510197
13.

Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ.

Am J Clin Oncol. 2008 Apr;31(2):133-9. doi: 10.1097/COC.0b013e318145b98b.

PMID:
18391596
14.

Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.

Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, Ferrari G, Annessi V, Lasagni D, Carbonelli C, De Franco S, Brini M, Sgarbi G, Lodi R.

Lung Cancer. 2009 Apr;64(1):92-7. doi: 10.1016/j.lungcan.2008.07.012. Epub 2008 Sep 19.

PMID:
18804892
16.

Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer.

de Castro J, Rodríguez MC, Martínez-Zorzano VS, Llanillo M, Sánchez-Yagüe J.

Exp Mol Pathol. 2009 Dec;87(3):226-33. doi: 10.1016/j.yexmp.2009.08.002. Epub 2009 Sep 3.

PMID:
19733167
17.

Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.

Chantapet P, Riantawan P, Lebnak P, Getngern P.

J Med Assoc Thai. 2000 Apr;83(4):383-91.

PMID:
10808698
18.

Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome.

Wang CL, Wang CI, Liao PC, Chen CD, Liang Y, Chuang WY, Tsai YH, Chen HC, Chang YS, Yu JS, Wu CC, Yu CJ.

J Proteome Res. 2009 Oct;8(10):4428-40. doi: 10.1021/pr900160h.

PMID:
19655816
19.

[Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients].

Ma L, Yue W, Zhang L, Wang Y, Zhang C, Yang X.

Zhongguo Fei Ai Za Zhi. 2010 Jul;13(7):706-12. doi: 10.3779/j.issn.1009-3419.2010.07.09. Chinese.

20.

[Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)].

Huang F, Wang XL, Geng Y, Li MX.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2005 Jul;21(4):507-9. Chinese.

PMID:
15989803

Supplemental Content

Support Center